Literature DB >> 28362716

PharmGKB summary: sorafenib pathways.

Li Gong1, Marilyn M Giacomini, Craig Giacomini, Michael L Maitland, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28362716      PMCID： PMC5418090          DOI： 10.1097/FPC.0000000000000279

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  74 in total

Review 1.  Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.

Authors:  Andrea Mancuso; Alessandra Mazzola; Giuseppe Cabibbo; Giovanni Perricone; Marco Enea; Antonio Galvano; Claudio Zavaglia; Luca Belli; Calogero Cammà
Journal:  Dig Liver Dis       Date:  2015-01-12       Impact factor: 4.088

2.  siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors.

Authors:  Amina Haouala; Holger Rumpold; Gerold Untergasser; Thierry Buclin; Hans-Beat Ris; Nicolas Widmer; Laurent A Decosterd
Journal:  Drug Metab Lett       Date:  2010-04

Review 3.  Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Authors:  Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz
Journal:  Oncologist       Date:  2007-04

4.  Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Authors:  Brandon Swift; Noelia Nebot; Jin Kyung Lee; Tianxiang Han; William R Proctor; Dhiren R Thakker; Dieter Lang; Martin Radtke; Mark J Gnoth; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-03-12       Impact factor: 3.922

5.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

6.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

7.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

8.  Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.

Authors:  Daniel Grimm; Jonas Lieb; Veronika Weyer; Johanna Vollmar; Felix Darstein; Anja Lautem; Maria Hoppe-Lotichius; Sandra Koch; Arno Schad; Jörn M Schattenberg; Marcus A Wörns; Arndt Weinmann; Peter R Galle; Tim Zimmermann
Journal:  BMC Cancer       Date:  2016-02-12       Impact factor: 4.430

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Authors:  Kelly E Caudle; Teri E Klein; James M Hoffman; Daniel J Muller; Michelle Whirl-Carrillo; Li Gong; Ellen M McDonagh; Katrin Sangkuhl; Caroline F Thorn; Matthias Schwab; Jose A G Agundez; Robert R Freimuth; Vojtech Huser; Ming Ta Michael Lee; Otito F Iwuchukwu; Kristine R Crews; Stuart A Scott; Mia Wadelius; Jesse J Swen; Rachel F Tyndale; C Michael Stein; Dan Roden; Mary V Relling; Marc S Williams; Samuel G Johnson
Journal:  Curr Drug Metab       Date:  2014-02       Impact factor: 3.731
View more
  18 in total

1.  An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.

Authors:  Chao Cheng; Yanding Zhao; Evelien Schaafsma; Yi-Lan Weng; Christopher Amos
Journal:  Int J Cancer       Date:  2020-06-04       Impact factor: 7.396

Review 2.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

Review 3.  Adverse events of sorafenib in hepatocellular carcinoma treatment.

Authors:  Yongsheng Pang; Aydin Eresen; Zigeng Zhang; Qiaoming Hou; Yining Wang; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

4.  Blocking autophagy with chloroquine aggravates lipid accumulation and reduces intracellular energy synthesis in hepatocellular carcinoma cells, both contributing to its anti-proliferative effect.

Authors:  Fengming Xu; Hans-Michael Tautenhahn; Olaf Dirsch; Uta Dahmen
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-13       Impact factor: 4.322

5.  Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model.

Authors:  Polina Suter; Eva Dazert; Jack Kuipers; Charlotte K Y Ng; Tuyana Boldanova; Michael N Hall; Markus H Heim; Niko Beerenwinkel
Journal:  PLoS Comput Biol       Date:  2022-09-06       Impact factor: 4.779

6.  Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.

Authors:  I-Tsang Chiang; Yu-Chang Liu; Hua-Shan Liu; Ahmed Atef Ahmed Ali; Szu-Yi Chou; Tsung-I Hsu; Fei-Ting Hsu
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

Review 7.  Involvement of cytochrome P450 enzymes in inflammation and cancer: a review.

Authors:  Maria Carolina Stipp; Alexandra Acco
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-28       Impact factor: 3.333

Review 8.  Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.

Authors:  Elena De Mattia; Erika Cecchin; Michela Guardascione; Luisa Foltran; Tania Di Raimo; Francesco Angelini; Mario D'Andrea; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2019-08-07       Impact factor: 5.742

9.  Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.

Authors:  Agnieszka Karbownik; Danuta Szkutnik-Fiedler; Andrzej Czyrski; Natalia Kostewicz; Paulina Kaczmarska; Małgorzata Bekier; Joanna Stanisławiak-Rudowicz; Marta Karaźniewicz-Łada; Anna Wolc; Franciszek Główka; Edmund Grześkowiak; Edyta Szałek
Journal:  Pharmaceutics       Date:  2020-06-28       Impact factor: 6.321

Review 10.  Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma.

Authors:  Michela Guardascione; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.